EC Microbiology

Paracetamol, also known as acetaminophen, is one of the most widely used over-the-counter analgesics and antipyretics globally. While generally considered safe when used as directed, excessive or prolonged use of paracetamol can lead to adverse effects on various organ systems within the human body. This comprehensive review explores the physiological mechanisms underlying paracetamol toxicity, its effects on different organs, risk factors for overdose, diagnostic methods, and potential management strategies.

 Keywords: Paracetamol; Human Body; Overdose; Toxicity; N-Acetyl-P-Benzoquinone Imine (NAPQI)

1. Ogemdi IK. “A review on the properties and uses of paracetamol”. International Journal of Pharmacy and Chemistry3 (2019): 31-35.
2. Brownson RC., et al. “Measuring the built environment for physical activity: state of the science”. American Journal of Preventive Medicine4 (2009): S99-S123.e12.
3. Lindon JC., et al. “Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis”. Biomarkers1 (2004): 1-31.
4. Barbour RS and M Barbour. “Evaluating and synthesizing qualitative research: the need to develop a distinctive approach”. Journal of Evaluation in Clinical Practice2 (2003): 179-186.
5. Wintzingerode F., et al. “Determination of microbial diversity in environmental samples: pitfalls of PCR-based rRNA analysis”. FEMS Microbiology Reviews3 (1997): 213-229.
6. Graham GG., et al. “The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings”. Inflammopharmacology3 (2013): 201-232.
7. Graham GG., et al. “Tolerability of paracetamol”. Drug Safety3 (2005): 227-240.
8. Bessems JG and NP Vermeulen. “Paracetamol (acetaminophen)-induced toxicity: molecular and biochemical mechanisms, analogues and protective approaches”. Critical Reviews in Toxicology1 (2001): 55-138.
9. Mazaleuskaya LL., et al. “PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses”. Pharmacogenetics and Genomics8 (2015): 416-426.
10. Vairetti M., et al. “Changes in glutathione content in liver diseases: an update”. Antioxidants3 (2021): 364.
11. Yoon E., et al. “Acetaminophen-induced hepatotoxicity: a comprehensive update”. Journal of Clinical and Translational Hepatology2 (2016): 131-142.
12. Rotundo L and N Pyrsopoulos. “Liver injury induced by paracetamol and challenges associated with intentional and unintentional use”. World Journal of Hepatology4 (2020): 125-136.
13. Locci C., et al. “Paracetamol overdose in the newborn and infant: a life-threatening event”. European Journal of Clinical Pharmacology 6 (2021): 809-815.
14. Fathelrahman AI. “Ten challenges associated with management of paracetamol overdose: an update on current practice and relevant evidence from epidemiological and clinical studies”. Journal of Clinical and Diagnostic Research3 (2021): FE01-FE06.
15. Squires JE., et al. “North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition position paper on the diagnosis and management of pediatric acute liver failure”. Journal of Pediatric Gastroenterology and Nutrition1 (2022): 138-158.
16. Chowdhury A., et al. “Current etiological comprehension and therapeutic targets of acetaminophen-induced hepatotoxicity”. Pharmacological Research 161 (2020): 105102.
17. Gopinathan S. “Molecular mechanisms of liver injury induced by hepatotoxins”. European Journal of Biomedical 11 (2016): 229-237.
18. Du K., et al. “Oxidative stress during acetaminophen hepatotoxicity: Sources, pathophysiological role and therapeutic potential”. Redox Biology 10 (2016): 148-156.
19. Jaeschke H., et al. “Mitochondrial damage and biogenesis in acetaminophen-induced liver injury”. Liver Research3-4 (2019): 150-156.
20. Urrunaga NH., et al. “M1 muscarinic receptors modify oxidative stress response to acetaminophen-induced acute liver injury”. Free Radical Biology and Medicine 78 (2015): 66-81.
21. Ramachandran A and H Jaeschke. “A mitochondrial journey through acetaminophen hepatotoxicity”. Food and Chemical Toxicology 140 (2020): 111282.
22. Mahadevan SB., et al. “Paracetamol induced hepatotoxicity”. Archives of Disease in Childhood7 (2006): 598-603.
23. Craig DG., et al. “Overdose pattern and outcome in paracetamol‐induced acute severe hepatotoxicity”. British Journal of Clinical Pharmacology2 (2011): 273-282.
24. Burcham PC and PC Burcham. “Target-organ toxicity: liver and kidney”. An Introduction to Toxicology (2014): 151-187.
25. Ramos-Tovar E and P Muriel. “Molecular mechanisms that link oxidative stress, inflammation, and fibrosis in the liver”. Antioxidants12 (2020): 1279.
26. Riordan SM and R Williams. “Alcohol exposure and paracetamol‐induced hepatotoxicity”. Addiction Biology2 (2002): 191-206.
27. Tompkins LM and H Wang. “Liver drug metabolism”. Oral Bioavailability: Basic Principles, Advanced Concepts, and Applications (2011): 127-144.
28. Kholili U., et al. “Liver injury associated with acetaminophen: A review”. Research Journal of Pharmacy and Technology4 (2023): 2006-2012.
29. Bhattacharyya S., et al. “Cytochrome P450s: mechanisms and biological implications in drug metabolism and its interaction with oxidative stress”. Current Drug Metabolism7 (2014): 719-742.
30. Stefanello ST., et al. “Acetaminophen oxidation and inflammatory markers-a review of hepatic molecular mechanisms and preclinical studies”. Current Drug Targets12 (2020): 1225-1236.
31. Karunarathna I., et al. “Advancements in the management of acute liver failure: pathophysiology, diagnosis, and treatment strategies”. Uva Clinical Lab (2024).
32. Angeli P., et al. “EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis”. Journal of Hepatology2 (2018): 406-460.
33. Agrawal S., et al. “Evaluation of abnormal liver function tests”. Postgraduate Medical Journal1086 (2016): 223-234.
34. Rumack BH and DN Bateman. “Acetaminophen and acetylcysteine dose and duration: past, present and future”. Clinical Toxicology2 (2012): 91-98.
35. Vipani A., et al. “Treatment of severe acute on chronic liver failure: management of organ failures, investigational therapeutics, and the role of liver transplantation”. Journal of Clinical Gastroenterology8 (2021): 667-676.
36. Wang X., et al. “Paracetamol: overdose-induced oxidative stress toxicity, metabolism, and protective effects of various compounds in vivo and in vitro”. Drug Metabolism Reviews4 (2017): 395-437.
37. Whelton A. “Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications”. The American Journal of Medicine5 (1999): 13S-24S.
38. Pakravan N. “Paracetamol poisoning and its treatment in man” (2008).
39. Waring WS and A Moonie. “Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury”. Clinical Toxicology8 (2011): 720-728.
40. Chambers JK. “Fluid and electrolyte problems in renal and urologic disorders”. Nursing Clinics of North America4 (1987): 815-826.
41. Mazer M and J Perrone. “Acetaminophen-induced nephrotoxicity: pathophysiology, clinical manifestations, and management”. Journal of Medical Toxicology1 (2008): 2-6.
42. Mostbeck GH., et al. “Ultrasound of the kidney: obstruction and medical diseases”. European Radiology10 (2001): 1878-1889.
43. Prowle JR., et al. “Fluid balance and acute kidney injury”. Nature Reviews Nephrology2 (2010): 107-115.
44. Paden ML., et al. “Recovery of renal function and survival after continuous renal replacement therapy during extracorporeal membrane oxygenation”. Pediatric Critical Care Medicine2 (2011): 153-158.
45. Alchin J., et al. “Why paracetamol (acetaminophen) is a suitable first choice for treating mild to moderate acute pain in adults with liver, kidney or cardiovascular disease, gastrointestinal disorders, asthma, or who are older”. Current Medical Research and Opinion5 (2022): 811-825.
46. Fanelli A., et al. “Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications”. Therapeutic Advances in Drug Safety6 (2017): 173-182.
47. Fulton RL., et al. “Acetaminophen use and risk of myocardial infarction and stroke in a hypertensive cohort”. Hypertension5 (2015): 1008-1014.
48. Moore N. “Coronary risks associated with diclofenac and other NSAIDs: an update”. Drug Safety4 (2020): 301-318.
49. Aksu K., et al. “Inflammation-induced thrombosis: mechanisms, disease associations and management”. Current Pharmaceutical Design11 (2012): 1478-1493.
50. McCrae J., et al. “Long‐term adverse effects of paracetamol–a review”. British Journal of Clinical Pharmacology10 (2018): 2218-2230.
51. Hassan-Ahmed M. “Renal function in a rat model of an analgesic nephropathy: Effect of chloroquine”. The University of Manchester (United Kingdom) (2002).
52. Fokunang C., et al. “Overview of non-steroidal anti-inflammatory drugs (nsaids) in resource limited countries”. MOJ Toxicology1 (2018): 5-13.
53. Graham G and M Hicks. “Pharmacokinetics and metabolism of paracetamol (acetaminophen), in Aspirin and related drugs”. Taylor and Francis London (2004): 181-213.
54. Hassan MN. “A study on drug’s side effects due to using GIT drugs without prescription in lower class people in Bangladesh”. East West University (2017).
55. Pasupuleti VR., et al. “Honey, propolis, and royal jelly: a comprehensive review of their biological actions and health benefits”. Oxidative Medicine and Cellular Longevity (2017): 1259510.
56. Sostres C., et al. “Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract”. Best Practice and Research Clinical Gastroenterology2 (2010): 121-132.
57. Penrose AJ. “Investigating the role of eyes absent homolog 1 (EYA1) in aspirin-induced gastric ulceration”. The University of Liverpool (United Kingdom) (2019).
58. Wehling M. “Non-steroidal anti-inflammatory drug use in chronic pain conditions with special emphasis on the elderly and patients with relevant comorbidities: management and mitigation of risks and adverse effects”. European Journal of Clinical Pharmacology10 (2014): 1159-1172.
59. Davis MP. “Drug management of visceral pain: concepts from basic research”. Pain Research and Treatment (2012): 265605.
60. Goodoory VC., et al. “Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome”. Alimentary Pharmacology and Therapeutics10 (2022): 1311-1319.
61. Kress HG and G Untersteiner. “Clinical update on benefit versus risks of oral paracetamol alone or with codeine: still a good option?” Current Medical Research and Opinion2 (2017): 289-304.
62. Jasat H., et al. “Prolonged use of paracetamol and the prescribing patterns on rehabilitation facilities”. Journal of Clinical Nursing23-24 (2022): 3605-3616.
63. Yew W. “Clinically significant interactions with drugs used in the treatment of tuberculosis”. Drug Safety2 (2002): 111-113.
64. Caparrotta TM., et al. “Are some people at increased risk of paracetamol-induced liver injury? A critical review of the literature”. European Journal of Clinical Pharmacology 2 (2018): 147-160.
65. Mitchell SJ., et al. “Age-related changes in the hepatic pharmacology and toxicology of paracetamol”. Current Gerontology and Geriatrics Research (2011): 624156.
66. Schmidt LE. “Paracetamol self-poisoning among adolescents in a department of hepatology”. International Journal of Adolescent Medicine and Health4 (2001): 327-334.
67. Rabinovitz M and DH Van Thiel. “Hepatotoxicity of nonsteroidal anti-inflammatory drugs”. American Journal of Gastroenterology (Springer Nature)12 (1992): 1696-1704.
68. Kozer E and G Koren. “Management of paracetamol overdose: current controversies”. Drug Safety 24 (2001): 503-512.
69. Roberts DM and NA Buckley. “Pharmacokinetic considerations in clinical toxicology: clinical applications”. Clinical Pharmacokinetics11 (2007): 897-939.
70. Gowda S., et al. “A review on laboratory liver function tests”. The Pan African Medical Journal 3 (2009): 17.
71. Tripodi A., et al. “The prothrombin time test as a measure of bleeding risk and prognosis in liver disease”. Alimentary Pharmacology and Therapeutics2 (2007): 141-148.
72. Bora A., et al. “Assessment of liver volume with computed tomography and comparison of findings with ultrasonography”. Abdominal Imaging6 (2014): 1153-1161.
73. Pettie J and M Dow. “Assessment and management of paracetamol poisoning in adults”. Nursing Standard45 (2013): 39-47.
74. Dart RC., et al. “Acetaminophen poisoning: an evidence-based consensus guideline for out-of-hospital management”. Clinical Toxicology1 (2006): 1-18.
75. Higgs A., et al. “Guidelines for the management of tracheal intubation in critically ill adults”. British Journal of Anaesthesia2 (2018): 323-352.
76. Chomchai S., et al. “Sensitivity of dose‐estimations for acute acetaminophen overdose in predicting hepatotoxicity risk using the Rumack‐Matthew Nomogram”. Pharmacology Research and Perspectives1 (2022): e00920.
77. Jones AL. “Mechanism of action and value of N-acetylcysteine in the treatment of early and late acetaminophen poisoning: a critical review”. Journal of Toxicology: Clinical Toxicology4 (1998): 277-285.
78. Tenório MCdS., et al. “N-acetylcysteine (NAC): impacts on human health”. Antioxidants6 (2021): 967.
79. Thorpy MJ and Y Dauvilliers. “Clinical and practical considerations in the pharmacologic management of narcolepsy”. Sleep Medicine1 (2015): 9-18.
80. Thummel KE., et al. “Design and optimization of dosage regimens: pharmacokinetic data”. Goodman & Gilman’s the pharmacological basis of therapeutics 11 (2006): 1787-1888.
81. Makin A and R Williams. “The current management of paracetamol overdosage”. International Journal of Clinical Practice3 (1994): 144-148.
82. Schultze AE., et al. “Clinical pathology in nonclinical toxicity testing”. In Haschek and Rousseaux's Handbook of Toxicologic Pathology (2022): 295-334.
83. Taylor BE., et al. “Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (ASPEN)”. Critical Care Medicine2 (2016): 390-438.
84. Karunarathna I., et al. “Advancements in the management of acute liver failure: pathophysiology, diagnosis, and treatment strategies”. Uva Clinical Lab (2024).
85. Polson J and WM Lee. “AASLD position paper: the management of acute liver failure”. Hepatology 5 (2005): 1179-1197.